FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:763-764 February 20, 2003 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Steinbrook, R. PubMed Citation

To the Editor: The development of medications appropriately adapted for the health needs of children should not be focused exclusively on national regulatory structures. Steinbrook (Oct. 31 issue)¹ correctly points out the strong gains made in the United States during the past five years through the development of both requirements and incentives for research in pediatrics. At the same time, as he indicates, children involved in studies threaten to slip through the gaps when government programs are not properly complemented by robust ethical frameworks for clinical trials involving children.

The ethical and safety challenges faced by parents, pediatricians, and authorities . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.